Dear Doctor Anaplastic lymphoma kinase positive (ALK+) lung cancer is a relatively rare subtype, occurring in about 1 in 25 cases with non-small-cell lung cancer (NSCLC), constituting approximately 85% of all lung cancer cases worldwide. Inhibitors designed for the ALK gene, such as crizotinib, alectinib, brigatinib, and lorlatinib, have demonstrated significant potential in NSCLC treatment.1, 2 We would like to hear your thoughts on the current treatment practices and your preferred management approach for NSCLC patients.
Here’s a survey on this topic that’ll take only two minutes to fill! Do share your experience and insights with us.